Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost

• Published in: European journal of ophthalmology Vol. 18; no. 4; p. 556
• Main Authors: Mulaney, J, Sonty, S, Ahmad, A, Stewart, J A, Stewart, W C
• Format: Journal Article
• Language: English
• Published: United States 01.07.2008
• Subjects: Aged; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - adverse effects; Circadian Rhythm; Drug Combinations; Female; Glaucoma, Open-Angle - drug therapy; Humans; Intraocular Pressure - drug effects; Male; Prospective Studies; Prostaglandins F, Synthetic - administration & dosage; Prostaglandins F, Synthetic - adverse effects; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Thiophenes - administration & dosage; Thiophenes - adverse effects; Timolol - administration & dosage; Timolol - adverse effects; Tonometry, Ocular; Treatment Outcome
• ISSN: 1120-6721
• DOI: 10.1177/112067210801800409

To compare the 12-hour efficacy and safety of dorzolamide/timolol fixed combination (DTFC) dosed twice daily versus latanoprost dosed every evening following a timolol run-in in primary open-angle glaucoma patients. Following a 6-week timolol run-in patients were randomized to either DTFC or latanoprost for 6 weeks and then changed to the opposite treatment for 6 weeks. At the end of the run-in, and the end of each treatment period, the intraocular pressure (IOP) was measured every 2 hours between 8:00 AM and 8:00 PM. Thirty-one patients completed at least one time point in both treatment periods. Both treatments reduced the IOP for the diurnal curve, and at each time point, from the timolol run-in baseline (p<0.0001). The 12-hour IOP on timolol was 22.1+/-2.8 mmHg, whereas on DTFC it was 18.1+/-2.8 and latanoprost 18.3+/-3.1 mmHg (p=0.4). Further, there was no statistical difference in IOP between treatments at any time point (p< or =0.1). There was no statistical difference for any individual adverse event between treatments (p>0.05). This study suggests that following a timolol run-in both DTFC and latanoprost provide comparable daytime efficacy and safety.